MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 04-08-2026
Nurix Therapeutics Total Assets 2011-2026 | NRIX
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Nurix Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 688 M | 669 M | 356 M | 417 M | 477 M | 396 M | 44 M | 45.4 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 688 M | 44 M | 387 M |
Quarterly Total Assets Nurix Therapeutics
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 636 M | 688 M | 522 M | 592 M | 615 M | 669 M | 514 M | 511 M | 313 M | 356 M | 308 M | 351 M | 370 M | 417 M | 459 M | 394 M | 438 M | 477 M | 493 M | 518 M | 477 M | 396 M | 396 M | 396 M | 396 M | 44 M | 44 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 688 M | 44 M | 437 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M |  USA |
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M |  Germany |
 |
Allakos
ALLK
|
244 M | - | - | $ 28.6 M | USA |
 |
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
41.4 M | $ 4.58 | - | $ 11 B |  Australia |
 |
Akouos
AKUS
|
279 M | - | 0.23 % | $ 488 M | USA |
 |
AlloVir
ALVR
|
122 M | - | 4.14 % | $ 49.1 M | USA |
 |
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
5.74 M | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
18.2 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
18.7 M | $ 0.88 | - | $ 6.47 M | China |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
151 M | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
1.19 B | $ 22.67 | - | $ 3.76 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
107 M | - | - | $ 10.1 M | USA |
 |
AIkido Pharma
AIKI
|
113 M | - | 1.93 % | $ 17.4 M | USA |
 |
Applied Therapeutics
APLT
|
54.8 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
66.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Galectin Therapeutics
GALT
|
19.5 M | $ 2.32 | - | $ 148 M | USA |
 |
Greenwich LifeSciences
GLSI
|
4.09 M | $ 22.8 | - | $ 297 M | USA |
 |
Genmab A/S
GMAB
|
21.1 B | $ 26.79 | - | $ 16.8 B |  Danmark |
 |
Avenue Therapeutics
ATXI
|
2.93 M | - | -52.27 % | $ 4.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
Aeterna Zentaris
AEZS
|
21.4 M | - | 5.93 % | $ 314 M |  Canada |
 |
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M |  Israel |
 |
AgeX Therapeutics
AGE
|
6.95 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
62.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
14.7 M | - | 17.91 % | $ 11.1 M | USA |
 |
Atreca
BCEL
|
155 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioNTech SE
BNTX
|
22 B | $ 102.06 | - | $ 27.2 B | Germany |
 |
Brainstorm Cell Therapeutics
BCLI
|
1.02 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
325 M | - | -4.8 % | $ 255 M | USA |
 |
Innoviva
INVA
|
1.64 B | $ 23.69 | - | $ 1.6 B | USA |
 |
Aquestive Therapeutics
AQST
|
160 M | $ 4.09 | - | $ 437 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
433 M | $ 23.29 | - | $ 2.96 B | USA |
 |
Jaguar Health
JAGX
|
38.3 M | $ 0.24 | - | $ 560 K | USA |
 |
KalVista Pharmaceuticals
KALV
|
335 M | $ 19.24 | - | $ 1.04 B | Britain |
 |
Autolus Therapeutics plc
AUTL
|
589 M | $ 1.48 | - | $ 394 M | Britain |
 |
Kamada Ltd.
KMDA
|
379 M | $ 8.15 | - | $ 260 M | Israel |
 |
Aptose Biosciences
APTO
|
10 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Kazia Therapeutics Limited
KZIA
|
35 M | $ 11.85 | - | $ 1.57 B | Australia |
 |
AstraZeneca PLC
AZN
|
114 B | - | - | $ 96.9 B | Britain |
 |
AVROBIO
AVRO
|
101 M | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
9.51 M | $ 2.91 | - | $ 4.79 M | Israel |
 |
BeiGene, Ltd.
BGNE
|
8.19 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | USA |
 |
Evogene Ltd.
EVGN
|
20 M | $ 0.79 | -0.65 % | $ 27.9 M | Israel |